Welcome to our dedicated page for Alzamend Neuro SEC filings (Ticker: ALZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC filings on a clinical-stage biotech like Alzamend Neuro are anything but light reading. Trial milestones for AL001’s lithium cocrystal, AL002’s immunotherapy vaccine, detailed liquidity notes, and frequent equity raises are scattered across hundreds of pages. If you need prompt answers on dilution risk or when directors buy shares, scrolling through EDGAR can feel endless.
Stock Titan removes that barrier. Our AI delivers Alzamend Neuro annual report 10-K simplified, flags each Alzamend Neuro quarterly earnings report 10-Q filing, and decodes every Alzamend Neuro 8-K material events explained—all within minutes of release. For anyone Googling “Alzamend Neuro SEC filings explained simply,” this page is the answer. Interactive dashboards push Alzamend Neuro insider trading Form 4 transactions the moment they post, while plain-language notes satisfy queries like “understanding Alzamend Neuro SEC documents with AI.” You can also drill into “Alzamend Neuro Form 4 insider transactions real-time” or review the latest “Alzamend Neuro proxy statement executive compensation.”
Practical use cases are clear: set alerts for Alzamend Neuro executive stock transactions Form 4 before financing rounds, benchmark R&D spend with our Alzamend Neuro earnings report filing analysis, or compare risk-factor language across filings in seconds. With comprehensive coverage of every form—10-K, 10-Q, 8-K, S-1, SC 13D/G—and AI-powered summaries that explain filing meanings in straightforward terms, you save hours and gain confidence when evaluating this innovative neurotherapeutics developer.
Milton C. Ault III, a director and 10% owner of Alzamend Neuro (ALZN), reported multiple transactions on Form 4. On 07/23/25, his affiliate Ault Lending, LLC converted 332.7553 Series B preferred shares into 143,429 common shares at an effective price of $2.32. The same day it sold 59,516 shares at an average $2.9502; a further 9,621 shares were sold on 07/24/25 at $2.9349.
Following the transactions, Ault Lending holds 82,552 common shares. Including other entities controlled by Mr. Ault (direct 1,843; Ault Life Sciences Inc. 11,068; Ault Life Sciences Fund LLC 61), his aggregate beneficial ownership is ≈95,524 common shares. Derivative positions remain significant: 1,767.2447 Series B preferred shares (no expiration) and 45,569 warrants with strike prices ranging from $108 to $4,050 expiring 2025-2029.
The filing shows a net reduction of roughly 69,137 shares (-42% of the 07/23 conversion) in Ault Lending’s indirect stake. While the conversion eliminates some preferred stock—simplifying the capital structure—the concurrent sales by a large insider can be viewed as a bearish signal for near-term sentiment.
Alzamend Neuro, Inc. (ALZN) has filed an amended Form 144 (Form 144/A) disclosing the intent of an undisclosed shareholder to sell 939,281 shares of common stock through broker E*TRADE Financial on or about 14 July 2025 on the NASDAQ exchange. The filing lists an aggregate market value of US $3,005,699.20 for the proposed sale. For context, the company reports 2,896,432 shares outstanding, meaning the planned disposition represents roughly one-third of the free-trading equity base, a size that can materially influence trading liquidity and share-price dynamics.
The notice also details the historical acquisition of the securities: purchases span private placements, IPO participation, open-market buys, warrant exercises and a sizable 905,172-share commitment tied to Series B convertible preferred stock, plus 25,804 shares available via warrants. Although these convertible and warrant positions are not part of the current sale, their disclosure signals additional potential share supply.
Within the past three months the same party (identified in the filing as Ault Lending, LLC) sold 1,213 shares for gross proceeds of $6,138. No material adverse information is represented, and the seller certifies compliance with Rule 144.
Key takeaways for investors: (1) the block size is large relative to the float, introducing a possible overhang; (2) the transaction is a secondary sale—no new capital accrues to the company; (3) additional convertible and warrant holdings could expand the float further if exercised or converted. The filing is procedural, but the magnitude of the proposed sale makes it noteworthy for liquidity and near-term price action.
FAQ
What is the current stock price of Alzamend Neuro (ALZN)?
What is the market cap of Alzamend Neuro (ALZN)?
